A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospitalized Patients With Heart Failure and Impaired Systolic Function

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospitalized Patients With Heart Failure and Impaired Systolic Function

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs BMS 986231 (Primary)
  • Indications Acute heart failure
  • Focus Therapeutic Use
  • Acronyms STANDUP AHF
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Dec 2017 Planned End Date changed from 5 Apr 2019 to 2 Oct 2019.
    • 06 Dec 2017 Planned primary completion date changed from 5 Nov 2018 to 4 May 2019.
    • 04 Apr 2017 Planned End Date changed from 1 Feb 2019 to 5 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top